{
  "pmcid": "12140551",
  "sha256": "74c846c4f6f43ee1ab1d4ceef7cef5ced046d3949ed063ac61ad72352de79f4d",
  "timestamp_utc": "2025-11-09T23:27:56.764782+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 7.947008547008547,
    "reading_ease": 54.380398860398884,
    "word_count": 247
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of Isolated Hepatic Perfusion Versus Best Alternative Care for Uveal Melanoma Liver Metastases"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "In this multicenter, phase III randomised controlled trial, 93 patients with untreated isolated liver metastases from uveal melanoma were enrolled between 2013 and 2021."
      },
      "Participants": {
        "score": 2,
        "evidence": "93 patients with untreated isolated liver metastases from uveal melanoma"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients were randomised 1:1 to receive a one-time IHP treatment or BAC"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study assesses isolated hepatic perfusion (IHP) versus best alternative care (BAC) for overall survival (OS) and health-related quality of life (HRQOL)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoint was the 24-month OS rate."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "93 patients with untreated isolated liver metastases from uveal melanoma were enrolled between 2013 and 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "The intention-to-treat (ITT) analysis included 43 patients in the IHP group and 44 in the control group."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The 24-month OS rate was 46.5% in the IHP group versus 29.5% in the control group (P=0.12). Median OS was 21.7 months for IHP and 17.6 months for BAC (HR 0.64, 95% CI 0.37â€“1.10)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Severe adverse events occurred in 19.5% of IHP patients and 6.5% of BAC patients."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT01785316."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 22,
    "max_score": 25
  }
}